Home / Community / News

News

01/07/2018 - 3:51pm

Discovery of the holy grail for DM therapy development-- drug registration endpoints -- lies in the dogged pursuit and sharing of natural history data.

01/07/2018 - 3:43pm

A new study examines the role of the GSK3β—cyclin D3—CUGBP1 pathway in the pathogenesis of DM1 and its potential as a therapeutic target.

01/07/2018 - 3:29pm

Development of a mini gene tool facilitates the identification of candidate therapeutics targeted at dissociating MBNL from expanded CUG repeats.

01/07/2018 - 3:20pm

NIH has reissued the CREATE Bio, Blueprint Neurotherapeutics and NeuroNEXT initiatives, along with other initiatives that focus on biomarker development and clinical trial readiness, to support therapy development efforts.

12/11/2017 - 3:06pm

NINDS announces its intent to issue Funding Opportunity Announcements to support analytical validation of identified candidate biomarkers.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.